MAGELLAN LONGEVITY
HomeResearchStudy library › What is the effect of Astaxanthin (AST) on pro-inflammatory…
Study summary · Immunity, inflammation & resilience

What is the effect of Astaxanthin (AST) on pro-inflammatory cytokines, oxidative stress (OS) markers, and early pregnancy outcomes in infertile women with endometriosis undergoing assisted reproductive techniques (ART)?

In one paragraph

Astaxanthin Softgels, a randomized trial (Front Endocrinol 2023, PMID 37020589) — AST pretreatment can modulate inflammation and oxidative stress in infertile patients with endometriosis, and improve ART outcomes after 12 weeks of therapy. Scope: over 12 weeks, and the abstract states no limitations.

Source: Front Endocrinol 2023, PMID 37020589 ↗ · Research map · How Magellan grades evidence · evidence confidence: medium

Front Endocrinol · 2023 · PMID 37020589 · DOI 10.3389/fendo.2023.1144323

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Astaxanthin supplementation improved markers of inflammation and oxidative stress, and enhanced ART outcomes in infertile women with endometriosis.

The question

What is the effect of Astaxanthin (AST) on pro-inflammatory cytokines, oxidative stress (OS) markers, and early pregnancy outcomes in infertile women with endometriosis undergoing assisted reproductive techniques (ART)?

What they tested

The study hypothesized that Astaxanthin (AST) treatment would modulate inflammation and oxidative stress markers, and improve early pregnancy outcomes in infertile women with endometriosis undergoing ART.

How they did it

This was a randomized, triple-blind, placebo-controlled clinical trial involving 50 infertile women with stage III/IV endometriosis who were candidates for ART. Participants received 6 mg of AST per day for 12 weeks. Blood serum and follicular fluid (FF) samples were collected before and after treatment to measure pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and OS markers (MDA, SOD, CAT, TAC). ART outcomes were also compared between the groups.

What they found

After AST therapy, the treatment group showed increased serum levels of TAC (398.661 vs. 364.746) and SOD (13.458 vs. 9.040), and decreased serum MDA (14.619 vs. 15.939). Significantly lower serum levels of IL-1β (4.515 vs. 6.8760), IL-6 (5.516 vs. 5.0543), and TNF-α (2.520 vs. 2.968) were also observed. Additionally, AST supplementation led to an improved number of oocytes retrieved (14.60 vs. 9.84), mature (MII) oocytes (10.48 vs. 6.72), and high-quality embryos (4.52 vs. 2.72).

Changes in Oxidative Stress Markers and Oocyte Retrieval After AST Treatment
Values shown: Value
Serum TAC (After AST)398.661
Serum TAC (Before AST)364.746
Serum SOD (After AST)13.458
Serum SOD (Before AST)9.04
Serum MDA (After AST)14.619
Serum MDA (Before AST)15.939
Oocytes Retrieved (After AST)14.6
Oocytes Retrieved (Before AST)9.84

This chart illustrates the changes in key oxidative stress markers (TAC, SOD, MDA) and the number of oocytes retrieved in infertile women with endometriosis after 12 weeks of Astaxanthin treatment compared to before treatment.

What it means

AST pretreatment can modulate inflammation and oxidative stress in infertile patients with endometriosis, and improve ART outcomes after 12 weeks of therapy. These results suggest AST could be a potential therapeutic target for this patient population.

Limitations

The abstract does not explicitly state any limitations of the study.

Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.

“Increased serum levels of total antioxidant capacity and SOD were observed after astaxanthin”— from the published abstract, Front Endocrinol 2023

The paper at a glance

Magellan’s evidence labelraises antioxidant capacity, lowers MDA (our label for this citation — see PubMed for the paper’s own title and authors)
JournalFront Endocrinol
Year2023
PMID37020589 ↗
DOI10.3389/fendo.2023.1144323 ↗
TopicImmunity, inflammation & resilience

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Astaxanthin Softgels

In humans, randomized trials and meta-analyses most consistently show that astaxanthin lowers the lipid-peroxidation marker malondialdehyde (MDA) and raises total antioxidant capacity and superoxide-dismutase activity, with additional signals for modest improvements in skin moisture and elasticity, fatigue, and some…

Astaxanthin Softgels

Astaxanthin is a reddish xanthophyll carotenoid produced mainly by the microalga Haematococcus…

Check price on Amazon ↗

Research describes the compound or intervention studied. It is not a claim about any specific product.

Molecules & mechanisms in this paper

Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). What is the effect of Astaxanthin (AST) on pro-inflammatory cytokines, oxidative stress (OS) markers, and early pregnancy outcomes in infertile women with endometriosis undergoing assisted reproductive techniques (ART)? [Plain-English summary of Front Endocrinol 2023, PMID 37020589, DOI 10.3389/fendo.2023.1144323]. Magellan Longevity. https://magellanlongevity.com/study/s107.html
BibTeX
@misc{magellan_s107, title = {What is the effect of Astaxanthin (AST) on pro-inflammatory cytokines, oxidative stress (OS) markers, and early pregnancy outcomes in infertile women with endometriosis undergoing assisted reproductive techniques (ART)?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/s107.html}}, note = {Plain-English summary of PubMed PMID 37020589; DOI 10.3389/fendo.2023.1144323; Front Endocrinol 2023. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/s107.html

Related studies in the Magellan library

All 17 Magellan summaries on immunity, inflammation & resilience →

How this summary was made. Every section above restates what the published abstract of PMID 37020589 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.